Medicines & supplements – Current GIS Alerts 2026
Found 735 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
PULNEO
It was determined that the benefit‑risk balance of medicinal products containing fenspiride, including Pulneo, is not favorable, which may pose a real threat to patients’ health or life. Potential effects: serious adverse reactions, threat to health or life.
EURESPAL
It was found that the benefit-risk balance of products containing fenspiride is unfavorable, meaning a risk of use disproportionate to the therapeutic effect and a potential threat to patients’ health or life. Potential effects: serious adverse reactions, life-threatening events, lack of safe therapy.
EURESPAL
A risk of use disproportionate to the therapeutic effect of the medicinal product Eurespal was identified, which may pose a direct threat to patients’ health or life. Potential effects: serious adverse reactions, threat to patients’ health or life.
FOSIDAL O SMAKU POMARAŃCZOWYM
It was found that the risk of using products containing fenspiride is disproportionate to their therapeutic effect, with a potential threat to patients’ health or life. Potential effects: serious adverse reactions, complications and life‑threatening events.
EURESPAL
A risk of use disproportionate to the therapeutic effect was identified for medicinal products containing fenspiride, meaning an unfavorable benefit–risk balance and potential health threat to patients. Potential effects: lack of treatment efficacy, complications from adverse reactions, risk to health or life.
EUREFIN
A risk of use of the medicinal product Eurefin disproportionate to its therapeutic effect was identified, meaning that the benefit–risk balance of medicines containing fenspiride is not favourable. Potential effects: serious adverse reactions, unacceptable safety profile, possible threat to patients’ health or life.
FENSPOGAL
A risk of use disproportionate to the therapeutic effect was identified for products containing fenspiride, considered by PRAC and CMDh significant enough to recommend withdrawal of marketing authorizations. Potential effects: serious adverse reactions, risk to health or life, unacceptable safety profile.
EURESPAL
No information in the text about a specific hazard, type of product defect, contamination, composition, or health risk for patients. Potential effects: impossible to assess risk, possible lack of efficacy or other undefined product-related issues.
Elofen
Determination of a risk of use disproportionate to the therapeutic effect of the medicinal product Elofen, with a significant probability of harm to individuals and a real, highly probable threat to patients’ health or life. Potential effects: serious adverse reactions, complications, threat to health or life, lack of a favorable benefit‑risk balance.
EURESPAL
A risk of using the medicinal product Eurespal disproportionate to its therapeutic effect was identified, which may cause a significant threat to patients’ health or life. Potential effects: treatment complications, lack of efficacy, possible serious adverse reactions.
FOSIDAL O SMAKU MALINOWYM
A risk of use disproportionate to the therapeutic effect of the product containing fenspiride was identified, which may pose a real and highly probable threat to patients’ health or life. Potential effects: treatment complications, serious adverse reactions, threat to health or life.
CURATODERM
A quality defect was found consisting of out-of-specification results for the active substance content parameter during stability testing of the medicinal product Curatoderm. Potential effects: lack of treatment efficacy or abnormal product action.
BDS N
Out-of-specification results were found in archival samples regarding the content of budesonide-related substances, due to exceeded levels of impurities. Potential effects: reduced treatment effectiveness or adverse effects related to the presence of impurities.
THIOGAMMA
A quality defect was found consisting in non-compliance of the disintegration parameter with the specification, which may mean improper release of the active substance and failure to ensure the established quality of the medicinal product. Potential effects: lack of treatment efficacy or its reduction.
BDS N
Out-of-specification results were found in archival samples for the parameter of budesonide-related substances content, due to exceeded impurity levels. Potential effects: possible adverse effects, toxicity, or lack of expected drug efficacy.
BDS N
Out-of-specification results were found in archival samples regarding the parameter "content of budesonide-related substances", due to exceeded impurity levels. Potential effects: possible adverse reactions, toxicity, or lack of expected therapeutic efficacy.
CLOPIDOGREL GENOPTIM
An incorrect name of the active substance was placed on the unit packaging, which may lead to medication errors and use of an inappropriate medicine or dose. Potential effects: lack of treatment efficacy, therapy complications, possible serious adverse reactions.
BUDIXON NEB
Exceedance of the specification limit for the content of budesonide-related substances was found for one batch and a probability of exceeding this limit for other batches of the product. Potential effects: lack of treatment efficacy or unpredictable adverse reactions.
BUDIXON NEB
Exceedance of the specification limit for the content of budesonide related substances was found in one batch and there is a probability of exceeding this limit in other batches of the product. Potential effects: possible lack of efficacy, unpredictable drug action, therapy complications.
BUDIXON NEB
Exceeding of specification limits for the content of budesonide related substances was found for batch 060218, with a probability of exceeding the limit for other batches still within shelf-life. Potential effects: lack of treatment efficacy, unpredictable adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.